Arecor to re­tain In­hi­brx roy­al­ties in wake of Sanofi ac­qui­si­tion

Last year
Deals

Up­dat­ed: Gilead’s Tecar­tus dropped from list of CAR-Ts with up­dat­ed boxed warn­ings

Last year
Pharma
Cell/Gene Tx

Ex­clu­sive: Reid Hu­ber re­unites with for­mer In­cyte col­league Wen­qing Yao, backs Syn­no­va­tion with $102M for three ...

Last year
Financing
Startups

Talc mar­ket­ing claims against J&J close to po­ten­tial set­tle­ment with 40+ states

Last year
Pharma
Law

Eli Lil­ly says its po­ten­tial gene ther­a­py 're­stored hear­ing' in 11-year-old boy

Last year
R&D
Cell/Gene Tx

Gilead clos­es $247M HIV drug set­tle­ment deal

Last year
Pharma
Law

J&J talks up $3B in deals that did­n't make head­lines in 2023

Last year
Deals
Pharma

Bi­par­ti­san group of law­mak­ers seeks to reign in phar­ma patent thick­ets with new bill

Last year
Pharma
FDA+

J&J still plans to scale up Carvyk­ti man­u­fac­tur­ing this year as it awaits FDA de­ci­sion on ex­pan­sion to ear­li­er lines

Last year
Pharma
Manufacturing

Mar­ket­ingRx roundup: Pfiz­er re­ups ba­by check­up cam­paign on so­cials; BI, Take­da on top em­ploy­ers list

Last year
Pharma
Marketing

No­vo Nordisk con­tin­ues to stack obe­si­ty pipeline, this time with Swiss ze­brafish biotech

Last year
Deals

Mer­ck inks deal with Un­nat­ur­al Prod­ucts; CG On­col­o­gy’s up­sized IPO; Lo­cus gets $24M from BAR­DA

Last year
News Briefing

What vir­tu­al phys­i­cal ther­a­py start­up Hinge Health wants in M&A

Last year
Health Tech

J&J meets Q4 ex­pec­ta­tions with $21.4B in sales as it stares down patent cliff

Last year
Pharma

Gene edit­ing de­liv­ery biotech GenEd­it part­ners with Genen­tech, rais­es an­oth­er $24M

Last year
Financing
Startups

Turquoise Health rais­es $30M to use AI to sort through health­care pric­ing da­ta

Last year
Health Tech

On­col­o­gy biotech Ac­cent rais­es $75M to en­ter the clin­ic

Last year
Financing
Startups

Up­dat­ed: FDA’s safe­ty re­view on CAR-Ts cul­mi­nates in new boxed warn­ings of sec­ondary can­cer

Last year
Pharma
Cell/Gene Tx

Sanofi wades in­to AATD in $1.7B bid for In­hi­brx's rare dis­ease drug

Last year
Deals
R&D

Au­to­lus eyes No­vem­ber for po­ten­tial US ap­proval of Tecar­tus ri­val

Last year
Pharma
Cell/Gene Tx

For clin­i­cian-ad­min­is­tered drugs, re­searchers find no as­so­ci­a­tion be­tween price in­creas­es and OOP cost in­creas­es

Last year
FDA+

FDA high­lights pri­or­i­ty re­view vouch­ers re­deemed as reau­tho­riza­tion lingers in Con­gress

Last year
Pharma
FDA+

Neu­ro com­pa­nies are one of phar­ma's hottest M&A as­sets. But be­hind the scenes, there have been few bid­ders

Last year
Deals
Pharma

No­var­tis' TV ad for breast can­cer drug Kisqali draws un­ti­tled let­ter from FDA

Last year
Pharma
FDA+
First page Previous page 213214215216217218219 Next page Last page
A service from the Financial Times